Argenx Se (ARGX) Retained Earnings (2015 - 2026)
Argenx Se's (ARGX) quarterly Retained Earnings came in at $558.0 million in Q2 2026, up 100.05% on a YoY basis from $278.9 million in Q2 2025, and up 299.29% quarter-over-quarter from -$280.0 million in Q4 2025.
Analysis
Argenx Se (ARGX) Retained Earnings (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Retained Earnings for 12 consecutive years, with $558.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Retained Earnings rose 100.05% year-over-year to $558.0 million; the trailing twelve-month figure through Jun 2026 stood at $558.0 million (up 100.05% YoY), and the FY2025 full-year result was -$280.0 million, up 99.98% from the prior year.
- Retained Earnings rose to $558.0 million in Q2 2026 per ARGX's latest filing, from -$280.0 million in the prior quarter.
- Across five years, Retained Earnings topped out at $558.0 million in Q2 2026 and bottomed at -$2109.8 billion in Q4 2022.
- Historically, Retained Earnings has averaged -$538.6 billion across 5 years, with a median of -$2.4 billion in 2023.
- The sharpest annual moves came in 2024 and 2026: Retained Earnings plunged 65259.92% in 2024, then jumped 100.05% in 2026.
- Over 5 years, Retained Earnings stood at -$2109.8 billion in 2022, then surged by 99.89% to -$2.4 billion in 2023, then slumped by 65259.92% to -$1571.8 billion in 2024, then surged by 99.98% to -$280.0 million in 2025, then jumped by 299.29% to $558.0 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $558.0 million, -$280.0 million, and -$1157.0 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | -22.28 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 9.53 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 15.69 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 37.62 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 558.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 20.97 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 6.57 Bn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | 19.31 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 558.00 Mn |
| Dec 31, 2025 | -280.00 Mn |
| Jun 30, 2025 | -1,156.98 Bn |
| Dec 31, 2024 | -1,571.80 Bn |
| Jun 30, 2024 | -2.44 Bn |
| Dec 31, 2023 | -2.40 Bn |
| Jun 30, 2023 | -2.23 Bn |
| Dec 31, 2022 | -2,109.79 Bn |
| Jun 30, 2022 | -1.84 Bn |
| Dec 31, 2021 | -1,400.20 Bn |
| Jun 30, 2021 | -928.76 Mn |
| Dec 31, 2020 | -1,027.15 Bn |
| Jun 30, 2020 | -592.81 Mn |
| Dec 31, 2019 | -368.12 Mn |
| Jun 30, 2019 | -241.27 Mn |
| Dec 31, 2018 | -193.58 Mn |
| Jun 30, 2018 | -146.84 Mn |
| Dec 31, 2017 | -118.41 Mn |
| Jun 30, 2017 | -88.72 Mn |
| Dec 31, 2016 | -78.27 Mn |